Extract from my post 10049645 below.It's becoming more relevant...

Extract from my post 10049645 below.

It's becoming more relevant each day, the trial progress is a bit of a concern, however if the cards fall our way and they do some fast tracking by taking into account Lani's time in the Japanese market then we could see a major upward share price rise.

My other concern is that global markets (in my opinion) are due for a major correction and Biota will not escape this but should recover quickly given it's potential earnings.


"My view is that Biota is a "no brainer" as Lani is already a proven drug in Japan both for prevention and flu treatment and has done it's time in the market over there in the last couple of years, with outstanding success as no Lani negatives have been reported.

So when, not if, Lani is approved worldwide, Biota earnings will be off the Richter scale.

Then what's the share price of Biota going to be?

Anything, given the high price of biotech stocks in the US earning nothing.

Over the next 18 months adult treatment trials will be completed and the results are a certainty, based on the already successful Japanese results and Lani use in the market.

The risk to Biota holders is basically nil, but the share price rise is surely awaiting us, I will be holding as this stock will make me very wealthy.

A bonus would be if they could fast track the Lani trials and get it to the world wide market sooner."